Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. VANI
VANI logo

VANI News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

VANI News

Cortigent's Brain Implant Device Receives FDA Approval

Jan 29 2026Newsfilter

Vivani Medical Prices $4.5M Offering for Growth Initiatives

Jan 26 2026seekingalpha

Vivani Medical Launches Stock Offering to Raise $4.5 Million

Jan 26 2026NASDAQ.COM

Vivani Medical's Cortigent Unveils Orion Visual Prosthesis Insights at NANS 2026

Jan 23 2026NASDAQ.COM

Cortigent's Orion Visual Stimulation System Completes 6-Year Feasibility Study

Jan 22 2026Newsfilter

Vivani Medical Shares Business Update and Announces Financial Results for Third Quarter 2025

Nov 13 2025Newsfilter

GNTA, BBIO, AMRN Surge in After-Hours Trading: Major Biotech Factors Fueling Stock Increases

Oct 29 2025NASDAQ.COM

Vivani Medical sets share price at $1.62 for $16M offering

Oct 27 2025SeekingAlpha

VANI Events

01/29 07:40
Vivani Medical Subsidiary Presents Orion Visual Cortical Prosthesis Study Results
Vivani Medical announced that Cortigent, its wholly-owned subsidiary developing brain implant devices, presented the results of a 6-year Early Feasibility Study of the Orion Visual Cortical Prosthesis System under development to deliver meaningful visual perception to blind persons at the North American Neuromodulation Society, NANS, annual meeting. NANS took place in Las Vegas, NV on January 22-25, 2026. The Orion system incorporates advanced neurostimulation technology and features a wirelessly powered and controlled implantable pulse generator connected to an array of 60 micro-electrodes designed for implantation on the surface of the brain involved in vision in blind patients. The system features a small processing unit worn on the belt that converts a real-time video stream captured by a camera embedded in specialized glasses into wireless commands to precisely stimulate neuron populations and elicit spots of light called phosphenes that provide visual perception.
11/13 07:47
Vivani Medical announces Q3 earnings per share of (11c), unchanged from last year.
Vivani Chief Executive Officer Adam Mendelsohn, Ph.D., stated, "Vivani achieved significant progress during the third quarter of 2025 including the successful completion of LIBERATE-1, marking the first clinical application of the Company's proprietary platform technology, NanoPortal(TM). This study paves the way for continued development of our growing pipeline of ultra long-acting miniature drug implants, including NPM-139 and NPM-133, our semaglutide-based implants in development for chronic weight management and treatment of type 2 diabetes, respectively. Our initial focus is on the Phase 1 study, which we anticipate will generate clinical data supporting both semaglutide development programs."
10/03 08:32
Vivani Medical cancels record date for Cortigent spin-off
Vivani Medical announced that the Company will temporarily withdraw the previously announced record date for the planned spin-off of Cortigent, its wholly-owned subsidiary developing brain implant devices with cutting-edge neuromodulation technology, due to delays arising from the current shutdown of the U.S. federal government. Vivani expects to reestablish and announce a new record date as soon as possible.

VANI Monitor News

No data

No data

VANI Earnings Analysis

No Data

No Data

People Also Watch